Klotho Neuroscience Inc. $(KLTO)$, a US-based biogenetics company, has announced a new clinical study in collaboration with the Okinawa Research Center for Longevity Science (ORCLS). The study aims to investigate the role of the human Klotho gene and its secreted protein isoform (s-KL) in promoting longevity and reducing the risks of neurodegenerative diseases, including ALS, Alzheimer's Disease, and Parkinson's Disease, as well as diabetes and cardiovascular disorders. The research will initially focus on analyzing blood levels of the Klotho protein in centenarian samples collected by ORCLS over several decades. Results of this study have not yet been presented and are expected to contribute to the understanding of how maintaining optimum Klotho protein levels may protect against age-related disorders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。